Small interfering RNA (siRNA) is a versatile tool for regulation of gene expression.[1] The ability of siRNA to silence translation and protein expression of cognate cellular mRNA provides the potential to regulate a wide array of therapeutically-relevant processes.[2] Despite the therapeutic promise of siRNA, there are challenges to its effective clinical and laboratory use.[3] Naked siRNA has low stability against nuclease activity and exhibits poor transfection efficacy due to its relatively large molecular weight and anionic character.[4] These challenges have been addressed using viral and synthetic delivery vehicles.[5] Viral delivery systems feature high transfection efficiencies,[6] however, these vectors can face challenges arising from immunogenicity[7] and mutagenicity.[8]
Non-viral siRNA delivery systems have the potential to provide improved safety and predictability relative to viral vectors,[9] and can be broken down into two major groups: covalently conjugated particles[10] and assemblies formed through electrostatic assembly with cationic materials.[11] Both strategies are effective, with the supramolecular strategy allowing the release of genetic material from the surface of the delivery vehicle into the cytosol following uptake, an important requirement for some applications.[12] A variety of cationic materials have been used to condense siRNA for delivery, including cationic lipids[13] and polymers.[14, 15]
Functionalized inorganic nanomaterials including carbon nanotubes,[16] iron oxide nanoparticles,[17] quantum dots,[18] and gold nanoparticles[19] provide alternative platforms for siRNA delivery, featuring diverse structures, sizes, core properties and ease of functionalization.[20] Additionally, these materials produce the structural properties of high molecular weight polymers using low molecular weight ligands, with the inorganic core functioning as a space-filling structural element for the presentation of the surface monolayer.[21] We hypothesized that reducing the bulk of the collapsible structure of a polymer to an inorganic nanoparticle would reduce the toxicity of the vehicle (by eliminating unnecessary exposable functionalities that are hidden during complexation), while retaining the favorable properties of polymer delivery vectors through proper functionalization of the surface monolayer. This is an important feature for siRNA delivery. Due to the small size of siRNA, the molecule experiences less efficient interactions with cationic delivery materials than plasmid-sized DNA. SiRNA therefore requires a greater number of vehicles per molecule, or a vehicle with a greater amount of cationic character. Both cases potentially lead to greater toxicity issues. We report here the use of gold nanoparticles featuring dendritic polyethylenimine-like ligands[22] to generate a supramolecular siRNA delivery vehicle featuring high knockdown efficiency and low toxicity.
Three different particles featuring gold cores (2 nm diameter) and triethylenetetramine (TETA) terminated dendron ligands were generated for this study via Murray place-exchange reaction (Scheme 1a).[23] The dendronized ligands feature biodegradable glutamic acid scaffolds and cationic TETA moieties that interact electrostatically with negatively charged siRNA (Scheme 1b). All three particles are cationic and resist aggregation as indicated by their zeta potentials. (Figure 1 and Figure S1).
Figure 1
Hydrodynamic diameter and zeta potential of G0-AuNP, G1-AuNP, and G2-AuNP. Gel retardation assay of AuNP/β-gal-siRNA complexation at different molar ratios showed a decrease in band intensity due to the fluorescence quenching by complexation with ...
Scheme 1
a) Chemical structures of G0-AuNP, G1-AuNP, and G2-AuNP. b) Schematic illustration of AuNP/ β-gal-siRNA complexation and transfection into cells.
The molar ratio of dendronized AuNPs to anionic siRNA required for efficient formation of condensed complexes was determined through an agarose gel retardation assay (Figure 1). All of the particles appeared to interact with siRNA, as band intensities associated with free siRNA fell with increasing concentrations of each. The G2 particle, however, appeared to be most efficient at retarding the electrophoretic mobility of siRNA, showing complete retardation at a NP/siRNA molar ratio of 2. Both the G0-AuNP and G1-AuNP still showed free siRNA bands at a NP/β-gal-siRNA ratio of 4 (Figure 1). In further experiments, we found that, when allowed to fully complex with siRNA, G0-AuNP/β-gal-siRNA and G1-AuNP/β-gal-siRNA complexes precipitated at these higher NP/β-gal-siRNA ratios, thus limiting their utility. These results indicate that tuning the degree of multivalency is important for generating AuNP/siRNA complexes that are useful for delivery applications. For this reason, G2-AuNP, capable of generating the most stable self-assembled nanoplexes with siRNA, was used for all subsequent studies. To confirm the condensation ratio between G2-AuNP and siRNA, an ethidium bromide (EtBr) fluorescence exclusion assay, in which the quenching of EtBr upon displacement by G2-AuNP, was performed (Figure S2). The corrected fluorescence curve likewise demonstrated the minimum binding ratio for G2-AuNP/β-gal-siRNA complexation was 2:1.
The G2-AuNP/β-gal-siRNA complexes were characterized by dynamic light scattering (DLS). Nanoplexes in ddH2O (double distilled water, MilliQ) were ~110 nm diameter (Figure S3). The assembly size increased to ~700 nm in a serum-containing media (OptiMEM®). The size (~825 nm) did not respond to significant changes even in the presence of media composed of 40% serum (Figure S4). Such changes are typical of supramolecular systems, which are easily affected by changes in pH, ionic strength (which can shield charges and alter the protonation state of surface ligands) and proteins (which can adsorb to the surfaces of nanoparticles and form supramolecular “coronas”).[24]
SiRNA mediated knockdown of β-galactosidase (β-gal) expression was studied using an enzyme activity assay in SVR-bag4 endothelial cells. To determine the optimal concentration of siRNA, SVR-bag4 cells were treated with G2-AuNP/β-gal siRNA at different concentrations (NP/siRNA = 2). β-gal silencing appeared to be saturated at G2-AuNP/β-gal-siRNA complex concentrations above 0.042 μM (Figure 2a). To investigate the correlation between gene silencing efficiency and NP/siRNA ratios, SVR-bag4 cells were also treated with a series of G2-AuNP/β-gal-siRNA complexes with molar ratios of 0.5, 1, and 2 (Figure 2b). Gene silencing was found to increase with NP/siRNA ratio, with maximum gene silencing (48%) observed in the case of completely complexed siRNA (NP/siRNA = 2). The knockdown efficiency observed for G2-AuNP/β-gal-siRNA at NP/siRNA 2 was similar to Lipofectamine™ (Invitrogen), a commercially available vehicle with a validated protocol. (Figure 2b). In the absence of either AuNP, siRNA, or a correct siRNA sequence, no significant suppression of β-gal was observed (Figure 2b).
Figure 2
β-gal gene silencing in SVR-bag4 cell. a) Gene silencing effect of G2-AuNP/β-gal-siRNA with different concentration from 0.021 to 0.084 μM (NP/siRNA=2). b) Gene silencing effect of naked β-gal siRNA, naked nonsense siRNA, ...
Cytotoxicity of both G2-AuNP and G2-AuNP/β-gal-siRNA complexes was evaluated by Alamar blue® assay. Again, SVR bag4 cells were used. Exposure of cells to the G2-AuNP alone for 2 days led to a slight decrease in cell viability (Figure 3a). Exposure of cells to G2-AuNP/β-gal-siRNA complexes for an identical period of time resulted in no significant toxicity (Figure 3b), likely through the charge-quenching effects of siRNA in the nanoparticle complex.
Figure 3
Cell viability determined by Alamar blue® assay. Cell viability was determined after the treatment of a) G2-AuNP and b) G2-AuNP/β-gal-siRNA complex at various molar ratios (β-gal siRNA=75 pmol).
In summary, we have demonstrated the utility of dendronized AuNPs as a vector for siRNA delivery. In these studies, G2-AuNP suppressed β-gal expression by ~ 50% with minimal toxicity. These nanoparticle vectors possess the benefits of polymeric delivery vehicles such as PEI, while minimizing toxicity through the use of non-toxic core functionality. The application of these systems in biotechnology and biomedicine are currently being explored and will be reported in due course.
[1]
Chad A Mirkin,et al.
Polyvalent DNA nanoparticle conjugates stabilize nucleic acids.
,
2020,
Nano letters.
[2]
T. Hobman,et al.
Exploring the functions of RNA interference pathway proteins: some functions are more RISCy than others?
,
2005,
The Biochemical journal.
[3]
R. Dias,et al.
DNA condensation by pH-responsive polycations.
,
2010,
Biomacromolecules.
[4]
Sang Bok Lee,et al.
Inorganic hollow nanoparticles and nanotubes in nanomedicine Part 1. Drug/gene delivery applications.
,
2007,
Drug discovery today.
[5]
Andreas Zimmer,et al.
Drug delivery of siRNA therapeutics: potentials and limits of nanosystems.
,
2009,
Nanomedicine : nanotechnology, biology, and medicine.
[6]
I. Wilson,et al.
Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity.
,
2000,
European journal of biochemistry.
[7]
B. S. Sekhon,et al.
Inorganic nanomedicine--part 1.
,
2010,
Nanomedicine : nanotechnology, biology, and medicine.
[8]
Vincent M Rotello,et al.
Efficient gene delivery vectors by tuning the surface charge density of amino acid-functionalized gold nanoparticles.
,
2008,
ACS nano.
[9]
Yu-Kyoung Oh,et al.
siRNA conjugate delivery systems.
,
2009,
Bioconjugate chemistry.
[10]
V. Rotello,et al.
Modulation of enzyme–substrate selectivity using tetraethylene glycol functionalized gold nanoparticles
,
2009,
Nanotechnology.
[11]
Leaf Huang,et al.
Nonviral methods for siRNA delivery.
,
2009,
Molecular pharmaceutics.
[12]
Xiang Gao,et al.
Nonviral Gene Delivery: Principle, Limitations, and Recent Progress
,
2009,
The AAPS Journal.
[13]
Tae Gwan Park,et al.
Intracellular trafficking and unpacking of siRNA/quantum dot-PEI complexes modified with and without cell penetrating peptide: confocal and flow cytometric FRET analysis.
,
2010,
Bioconjugate chemistry.
[14]
Xiaohu Gao,et al.
Quantum dot-amphipol nanocomplex for intracellular delivery and real-time imaging of siRNA.
,
2008,
ACS nano.
[15]
Elodie Boisselier,et al.
Gold nanoparticles in nanomedicine: preparations, imaging, diagnostics, therapies and toxicity.
,
2009,
Chemical Society reviews.
[16]
Chong-K. Kim,et al.
Polyethylenimine‐based antisense oligodeoxynucleotides of IL‐4 suppress the production of IL‐4 in a murine model of airway inflammation
,
2006,
The journal of gene medicine.
[17]
Alexander M. Klibanov,et al.
Conjugation to gold nanoparticles enhances polyethylenimine's transfer of plasmid DNA into mammalian cells
,
2003,
Proceedings of the National Academy of Sciences of the United States of America.
[18]
M. Manoharan,et al.
RNAi therapeutics: a potential new class of pharmaceutical drugs
,
2006,
Nature chemical biology.
[19]
Jianzhu Chen,et al.
A Novel Mechanism Is Involved in Cationic Lipid-Mediated Functional siRNA Delivery
,
2009,
Molecular pharmaceutics.
[20]
F. Kirchhoff.
Silencing HIV-1 In Vivo
,
2008,
Cell.
[21]
Y. Takakura,et al.
Nonviral vector-mediated RNA interference: its gene silencing characteristics and important factors to achieve RNAi-based gene therapy.
,
2009,
Advanced drug delivery reviews.
[22]
P. Murat,et al.
Recent developments in oligonucleotide conjugation.
,
2010,
Chemical Society reviews.
[23]
R. Murray,et al.
Monolayer-protected cluster molecules.
,
2000,
Accounts of chemical research.
[24]
Chad A Mirkin,et al.
Scavenger receptors mediate cellular uptake of polyvalent oligonucleotide-functionalized gold nanoparticles.
,
2010,
Bioconjugate chemistry.
[25]
M. Carmell,et al.
Posttranscriptional Gene Silencing in Plants
,
2006
.
[26]
G. Divita,et al.
A non-covalent peptide-based strategy for siRNA delivery.
,
2011,
Methods in molecular biology.
[27]
Thomas Tuschl,et al.
siRNAs: applications in functional genomics and potential as therapeutics
,
2004,
Nature Reviews Drug Discovery.
[28]
Qiao Jiang,et al.
Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte.
,
2010,
ACS nano.
[29]
T. Aminabhavi,et al.
Chitosan as a carrier for targeted delivery of small interfering RNA.
,
2010,
International journal of pharmaceutics.
[30]
Christopher R. Sibley,et al.
Novel RNA-based strategies for therapeutic gene silencing.
,
2010,
Molecular therapy : the journal of the American Society of Gene Therapy.
[31]
A. Göpferich,et al.
Polyethylenimine-based non-viral gene delivery systems.
,
2005,
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[32]
Shubiao Zhang,et al.
Hybrids of nonviral vectors for gene delivery.
,
2010,
Bioconjugate chemistry.
[33]
Huixin He,et al.
DNA and carbon nanotubes as medicine.
,
2010,
Advanced drug delivery reviews.
[34]
Shirui Mao,et al.
Gene delivery using chitosan, trimethyl chitosan or polyethylenglycol-graft-trimethyl chitosan block copolymers: establishment of structure-activity relationships in vitro.
,
2008,
Journal of controlled release : official journal of the Controlled Release Society.
[35]
Chad A. Mirkin,et al.
Gene regulation with polyvalent siRNA-nanoparticle conjugates.
,
2009,
Journal of the American Chemical Society.
[36]
M. Sullivan,et al.
Development of a novel gene delivery scaffold utilizing colloidal gold–polyethylenimine conjugates for DNA condensation
,
2003,
Gene Therapy.
[37]
K. High,et al.
Viral vector-mediated RNA interference.
,
2010,
Current opinion in pharmacology.
[38]
S. Akhtar,et al.
Nonviral delivery of synthetic siRNAs in vivo.
,
2007,
The Journal of clinical investigation.
[39]
John J. Rossi,et al.
The promises and pitfalls of RNA-interference-based therapeutics
,
2009,
Nature.